BA9™, an effective Cytostatic Limus Drug

Rapid 28 day BA9™ transfer to the vessel wall achieved through enhanced high lipophilicity delivering:
  • Greater Local Bioavailability
  • Targeted Drug Release
  • Local tissue warehousing allowing sustained tissue release, with therapeutic effect up to 100 days12,13
  • Longer half-life than other commonly used Limus drugs, approximately 20 days in tissue12,13
  • Potent Neointimal Suppression

Increasing Safety and Efficacy

By leaving a bare metal stent luminal surface, BioFreedom™ Ultra promotes rapid reendothelialization, improves the healing process14 and allows for ultra-short 1 month DAPT.


> More details about Biolimus A9™

11521-000-EN - Rev.01 + 11903-000-EN - Rev.01 + 11524-000-EN - Rev.01 + 11881-000-EN - Rev.04
Movie - How does it work?
Watch the working principle of our BA9™
BA9 brochure

12. Tada et al. Circulation: Cardiovascular Interventions. 2010;3:174-183
13. Internal BioFreedom Tissue PK Report
14. Rapid reedotheilalization is: Establishment of healing profile and neointimal transformation in the new polymer-free biolimus A9-coated coronary stent by longitudinal sequential optical coherence tomography assessments: the EGO-BIOFREEDOM study Lee SWL et al. EuroIntervention. 2018 Sep 20;14(7):780-788

CAUTION: Please note that the following pages are exclusively reserved for Health Care Professionals in countries with applicable health authority product registrations. To the extent this site contains information intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions. Please contact your Biosensors International representative for availability or the products and registration status.

The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology products, including BioMatrix NeoFlex™, BioMatrix™ Alpha, BioFreedom™, BioFreedom™ Ultra, BMX-J® and RISE™ NC, are not available for sale in the United States and certain other countries. ALLEGRA™ is a product of NVT GmbH. Blue Sail Medical Co., Ltd is the ultimate parent company of NVT GmbH and Biosensors International Group, Ltd. and its subsidiaries are collaborating for the commercialization of the ALLEGRA™ device.

BioMatrix NeoFlex, BioMatrix Alpha, BioFreedom, BioFreedom Ultra, BMX-J, Juno, S-Stent and Rise NC are trademarks or registered trademarks of Biosensors International Group, Ltd. ALLEGRA is a trademark or registered trademark of NVT AG. All other cited trademarks are the property of their respective owners.